voda schreef op 10 november 2017 21:10:
[...]
Even lezen:
www.glpg.com/press-releases"In the first three quarters of 2017 Galapagos continued to invest in its R&D pipeline to produce substantial progress. Delivery of the FLORA study results and the Phase 1b results with MOR106 solidified shareholder confidence in the future of our company and in our ability to execute," said Bart Filius, CFO. "With a cash position of €1.2 billion, we remain well positioned to advance our wide range of R&D programs. We anticipate our cash burn for the full year to be at the lower end of our guidance of €135 - 155 million."
Consolidated key figures Q3 report 2017 (unaudited)
(€ millions, except basic & diluted income/loss per share)
30 September 2017 30 September 2016
Revenues 106.4 65.0
R&D expenditure (149.2) (96.7)
G&A and S&M expenses (19.7) (16.8)
Operating loss (62.6) (48.5)
Non-cash adjustment on short term financial asset1 - 57.5
Other net financial result (23.1) (0.9)
Taxes (0.2) (0.1)
Net result for the period (85.9) 8.1
Basic income/loss (-) per share (€) (1.75) 0.18
Diluted income/loss (-) per share (€) (1.75) 0.17
Cash, cash equivalents and restricted cash 1,220.1 938.8